CD8A and melanoma: As for combination therapy, immune checkpoint therapies have emerged in the effective treatment of melanoma, and it is reported that immune checkpoint inhibitors and BRAF-targeted therapies have an effect on unresectable advanced melanoma.33–35 The result of the immunosuppressive model for B16F10 CDX showed that immunity synergistically promoted the antitumor efficacy of erianin with dramatic increases of CD8a+, CD4+ T cells, and NK cells (Fig. 7e, Supplementary Fig. S8e, k and l), which provides a proposal for combination therapy of erianin and checkpoint inhibitor.